| Botox (onabotulinumtoxin A) / GSK, AbbVie, Healis Therap |
NCT00682760: Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm |
|
|
| Completed | 3 | 60 | RoW | Korean Botulinum toxin type A (KbtxA) and Botox injection, arm1 ; Meditoxin or Neuronox | Pacific Pharmaceuticals | Blepharospasm | 02/06 | 08/06 | | |
NCT00408785: A Study Of BOTOX For The Treatment Of Glabellar Lines |
|
|
| Completed | 3 | 256 | RoW | Botulinum Toxin Type A, sodium chloride | GlaxoSmithKline | Glabellar Lines | 05/07 | 05/07 | | |
PREEMPT, NCT00156910: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches |
|
|
| Completed | 3 | 679 | US, Canada | Botulinum Toxin Type A, BOTOX®, Placebo (saline) | Allergan | Migraine Disorders | 11/07 | 07/08 | | |
|
|
|
|
|
|
|
|
PREEMPT, NCT00168428: A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches |
|
|
| Completed | 3 | 705 | US, Canada, Europe, RoW | Botulinum Toxin Type A, BOTOX®, placebo (saline) | Allergan | Migraine Disorders | 12/07 | 08/08 | | |
|
|
|
|
|
|
|
NCT00496964: Botox for Non-surgical Lateral Release in Patellofemoral Pain |
|
|
| Terminated | 3 | 5 | US | Botulinum toxin A + exercise, Botox, Placebo | Virginia Commonwealth University, Allergan | Patellofemoral Pain Syndrome | 06/08 | 06/08 | | |
2005-004637-17: A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase |
|
|
| Completed | 3 | 650 | Europe, RoW | BOTOX®, 9060X, Powder for solution for injection, BOTOX® | ALLERGAN LTD | Headache prophylaxis in migraine patients with 15 or more headache days per month | | 08/08 | | |
NCT00460564: Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 109 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Post-Stroke Spasticity, Cerebrovascular Accident | 12/08 | 12/08 | | |
NCT00460655: Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity |
|
|
| Completed | 3 | 120 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Post-Stroke Spasticity, Cerebrovascular Accident | 12/08 | 12/08 | | |
NCT01091727: Intravesical Injection of Botulinum Toxin A Versus Saline for Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 57 | Canada | Botulinum toxin A, Botox | Sunnybrook Health Sciences Centre, ethica Clinical Research Inc. | Neurogenic Detrusor Overactivity | 04/09 | 04/09 | | |
NCT00777803 / 2008-002713-40: NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines |
|
|
| Completed | 3 | 381 | Europe | NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®)), "Botulinum toxin type A (150 kiloDalton), free from complexing proteins", OnabotulinumtoxinA (Vistabel®), "BOTOX® Cosmetic", "Botulinum toxin type A (900 kiloDalton)" | Merz Pharmaceuticals GmbH | Glabellar Frown Lines | 04/09 | 05/09 | | |
NCT01791881: Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of "Hugeltox Inj." in Essential Blepharospasm |
|
|
| Completed | 3 | 172 | RoW | Hugeltox, Botulinum Toxin Type A(Botox®) | Hugel | Essential Blepharospasm | 05/09 | 07/09 | | |
NCT00461292: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
|
|
| Completed | 3 | 275 | US, Canada, Europe, RoW | botulinum toxin Type A (200U), BOTOX®, botulinum toxin Type A (300U), Normal saline (Placebo); botulinum toxin Type A (200U), Normal saline (Placebo); botulinum toxin Type A (300U) | Allergan | Overactive Bladder | 03/10 | 04/10 | | |
2007-000192-42: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment with Two Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex Followed by a Treatment with BOTOX® in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 275 | Europe, RoW | Botox®, 9060X, Powder for solution for injection, BOTOX® | Allergan Ltd, ALLERGAN | Urinary incontinence due to neurogenic detrusor overactivity | | | | |
| Completed | 3 | 416 | US, Canada, Europe, RoW | botulinum toxin Type A (200U), BOTOX®, botulinum toxin Type A (300U), Normal Saline (Placebo); botulinum toxin Type A (200U), Normal Saline (Placebo); botulinum toxin Type A (300U) | Allergan | Overactive Bladder | 05/10 | 05/10 | | |
NCT01237977: Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines |
|
|
| Completed | 3 | 314 | RoW | Botulinum Toxin Type A(Meditoxin®), Neuronox®, Siax®, Botulinum Toxin Type A(Botox®) | Medy-Tox | Skin Aging | 08/10 | 09/10 | | |
| Completed | 3 | 917 | Canada, US, Europe | onabotulinumtoxinA 24 U, BOTOX®, BOTOX® Cosmetic, onabotulinumtoxinA, onabotulinumtoxinA 44 U, normal saline | Allergan | Facial Rhytides, Crow's Feet Lines, Glabellar Lines | 03/11 | 09/11 | | |
| Completed | 3 | 446 | Canada, US, Europe | onabotulinumtoxinA, BOTOX®, BOTOX® Cosmetic, normal saline | Allergan | Lateral Canthus Rhytides, Crow's Feet Lines | 04/11 | 07/11 | | |
NCT01153815: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 170 | RoW | GSK1358820(Botulinum toxin type A), OnabotulinumtoxinA, Botox, placebo | GlaxoSmithKline | Cerebrovascular Accident | 06/11 | 06/11 | | |
NCT00910845: Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
|
|
| Completed | 3 | 557 | US, Canada | onabotulinumtoxinA, BOTOX®, botulinum toxin Type A, normal saline | Allergan | Overactive Bladder | 07/11 | 07/11 | | |
| Completed | 3 | 548 | US, Europe, RoW | onabotulinumtoxinA, BOTOX®, botulinum toxin Type A, normal saline | Allergan | Overactive Bladder | 08/11 | 08/11 | | |
NCT01128738: GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis |
|
|
| Completed | 3 | 152 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Hyperhidrosis | 08/11 | 08/11 | | |
| Completed | 3 | 684 | US, Canada, Europe | normal saline, onabotulinumtoxinA 44 U, BOTOX®, BOTOX® Cosmetic, onabotulinumtoxinA, onabotulinumtoxinA 24 U | Allergan | Facial Rhytides, Crow's Feet Lines, Glabellar Lines | 10/11 | 02/12 | | |
NCT01205451: A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity |
|
|
| Completed | 3 | 109 | RoW | Botulinum toxin type A | GlaxoSmithKline | Spasticity, Post-Stroke | 12/11 | 03/12 | | |
NCT01791920: To Evaluate the Safety and Efficacy of Botulax® Are Not Inferior to Those of Botox® in the Treatment of Glabellar Lines |
|
|
| Completed | 3 | 262 | RoW | Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®) | Hugel | Skin Aging | 12/11 | 03/12 | | |
NCT01313767: MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity |
|
|
| Completed | 3 | 196 | RoW | Botulinum toxin type A, Neuronox®, Siax®, Botulinum Toxin type A, Botox® | Medy-Tox | Spasticity | 01/12 | 02/12 | | |
NCT03894748: Efficacy and Safety Study of MT10109L in the Treatment of Glabella Line(Including a Preliminary Study to Evaluate Safety of MT10109L) |
|
|
| Completed | 3 | 168 | RoW | Botulinum Toxin Type A | Medy-Tox | Glabella Line Severity | 08/12 | 10/12 | | |
NCT01629875: Efficacy and Safety of DWP450 Compared With Botox in Moderate to Severe Glabellar Line |
|
|
| Completed | 3 | 268 | RoW | Generic equivalent of Clostridium Botulinum A Toxin, Botox (Clostridium Botulinum A Toxin) | Daewoong Pharmaceutical Co. LTD. | Moderate to Severe Glabellar Line | 08/12 | 11/12 | | |
NCT00439140: Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder |
|
|
| Terminated | 3 | 41 | US, Canada, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, Normal Saline (Placebo) | Allergan | Overactive Bladder | 12/12 | 12/12 | | |
| Terminated | 3 | 11 | Europe | Botulinum Toxin Type A, Botox, Placebo | Daniel Stephan Engeler, Allergan | Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Prostatitis | 05/13 | 06/13 | | |
NCT00876447 / 2009-009216-53: A Long-term Follow-up Study of Botulinum Toxin Type A in Patients With Overactive Bladder as a Result of Spinal Injury or Multiple Sclerosis |
|
|
| Completed | 3 | 397 | Canada, US, Europe, RoW | Botulinum Toxin Type A 300U, BOTOX®, Botulinum Toxin Type A 200U | Allergan | Overactive Bladder | 06/13 | 09/13 | | |
NCT01584843: Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus |
|
|
| Completed | 3 | 41 | Japan | GSK1358820, Botulinum Toxin Type A | GlaxoSmithKline | Strabismus | 07/13 | 06/14 | | |
NCT01797094: BOTOX® in the Treatment of Upper Facial Lines in Japan |
|
|
| Completed | 3 | 101 | Japan | botulinum toxin Type A (44U), BOTOX®, botulinum toxin Type A (32U) | Allergan | Upper Facial Rhytides, Crow's Feet Lines, Glabellar Lines, Frown Lines | 07/13 | 07/14 | | |
NCT01797081: BOTOX® in the Treatment of Crow's Feet Lines in Japan |
|
|
| Completed | 3 | 300 | Japan | botulinum toxin Type A (24 U), BOTOX®, botulinum toxin Type A (12 U), Normal Saline | Allergan | Lateral Canthus Rhytides, Crow's Feet Lines | 07/13 | 07/14 | | |
NCT01600716 / 2012-000957-30: Safety and Efficacy Study of OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Neurogenic Detrusor Overactivity (NDO) in Non-Catheterizing Patients With Multiple Sclerosis (MS) |
|
|
| Completed | 3 | 144 | Canada, US, Europe, RoW | OnabotulinumtoxinA, BOTOX®, botulinum toxin Type A, Placebo (Normal Saline) | Allergan | Urinary Incontinence, Multiple Sclerosis, Neurogenic Bladder | 04/14 | 03/15 | | |
NCT01915459: Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 186 | RoW | Botulinum toxin type A(Botulax®), Botulinum toxin type A(Botox®) | Hugel | Stroke, Spasticity | 05/14 | 07/14 | | |
NCT01945684: A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 197 | RoW | Botulinum toxin type A, Assigned Interventions, Experimental: DWP450, Botulinum toxin type A Drug: Botulinum toxin type A, Active Comparator: Botox®, Botulinum Toxin type A Drug: Botulinum Toxin type A (Botox®) | Daewoong Pharmaceutical Co. LTD. | Spasticity, Stroke | 05/14 | 07/14 | | |
NCT03908008: Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line |
|
|
| Completed | 3 | 136 | NA | Botox (Botulinum toxin type A), MT10107 (Botulinum toxin type A) | Medy-Tox | Glabellar Frown Lines | 05/14 | 09/14 | | |
NCT01787344: Phase III Clinical Trial of "Botulax®" to Treat Children With Cerebral Palsy |
|
|
| Completed | 3 | 144 | RoW | Botulinum Toxin Type A(Botox®), Botulinum toxin type A(Botulax®) | Hugel | Other Infantile Cerebral Palsy | 06/14 | 08/14 | | |
| Completed | 3 | 152 | NA | Medytoxin, botulinum type A toxin, Botox | Medy-Tox | Cervical Dystonia | 07/14 | 08/14 | | |
NCT00915525 / 2009-013089-26: Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence |
|
|
| Completed | 3 | 829 | Canada, US, Europe, RoW | botulinum toxin Type A, BOTOX® | Allergan | Overactive Bladder, Urinary Incontinence | 08/14 | 08/14 | | |
| Completed | 3 | 468 | US, Canada, Europe, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxin A, Normal Saline | Allergan | Muscle Spasticity | 09/14 | 07/15 | | |
NCT01767519 / 2012-003255-11: A Study Evaluating the Efficacy and Safety of BOTOX® or Solifenacin in Patients With Overactive Bladder and Urinary Incontinence |
|
|
| Completed | 3 | 356 | Canada, US, Europe, RoW | BOTOX®, onabotulinumtoxinA, botulinum toxin Type A, solifenacin, Vesicare, Botox placebo (normal saline), solifenacin placebo | Allergan | Overactive Bladder, Urinary Incontinence | 09/14 | 03/15 | | |
NCT02195687: BOTOX® in the Treatment of Crow's Feet Lines in China |
|
|
| Completed | 3 | 417 | RoW | botulinum toxin Type A, BOTOX®, Normal Saline | Allergan | Lateral Canthal Lines, Crow's Feet Lines | 02/15 | 06/15 | | |
| Completed | 3 | 787 | US, Europe | OnabotulinumtoxinA, BOTOX® Cosmetic, botulinum toxin Type A, Normal Saline | Allergan | Facial Rhytides, Glabellar Rhytides | 06/15 | 04/16 | | |
| Completed | 3 | 421 | Canada, US, Europe | OnabotulinumtoxinA, BOTOX® Cosmetic, botulinum toxin Type A, Normal Saline | Allergan | Forehead Rhytides, Glabellar Rhytides | 06/15 | 04/16 | | |
2014-002068-34: Residual Limb Hyperhidrosis Treatment : Aluminium Chloride versus Onabotulinumtoxin A Traitement de l’hyperhidrose des membres résiduels : sels d’aluminium versus toxine botulique |
|
|
| Ongoing | 3 | 54 | Europe | Powder for solution for injection, BOTOX, 100 units | DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES, DIRECTION CENTRALE DU SERVICE DE SANTE DES ARMEES | Residual Limb Hyperhidrosis is the investigated medical condition., Amputees often suffer from hyperhidrosis (important production of sweat), which is responsible for prosthesis function impairments, dermatological problems and quality of life impairments., Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
NCT02165111: Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome |
|
|
| Completed | 3 | 40 | US | Onabotulinumtoxin A, Botox, Botulinum toxin, Dysport, sterile saline solution, Saline | Johns Hopkins University, Allergan | Scleroderma, Raynaud's Syndrome | 09/15 | 09/15 | | |
NCT01422161: Study of Botulinum Toxin and Recovery of Hand Function After Stroke |
|
|
| Completed | 3 | 16 | US | Botulinum Toxin commonly known as BOTOX®, BOTOX®, Saline, Placebo | NYU Langone Health, Allergan | Stroke With Hemiparesis | 10/15 | 10/15 | | |
| Terminated | 3 | 53 | US, Canada | onabotulinumtoxinA, BOTOX®, botulinum toxin type A, placebo (normal saline) | Allergan | Muscle Spasticity, Stroke | 12/15 | 12/15 | | |
2006-006299-39: A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment |
|
|
| | 3 | 20 | Europe | BOTOX®, 9060X, BOTOX®, BOTOX® | Allergan | Patients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment. | | | | |
2014-001063-12: A clinical trial demonstrating the safety and efficacy of treatment of lines between the eye brows with the test drug DWP-450 in adults by comparison with Botox and Placebo. |
|
|
| Completed | 3 | 497 | Europe, RoW | Botox, DWP-450, Powder for solution for injection, Nabota, Botox, 100 Allergan Units | Evolus Inc., Evolus Inc. | moderate-to-severe glabellar lines, lines between the eyebrows and above the nose, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
NCT02450526: Dysport in the Treatment of Glabellar Lines in Chinese Subjects |
|
|
| Completed | 3 | 520 | RoW | Botulinum toxin type A, AbobotulinumtoxinA (Dysport®), OnabotulinumtoxinA (Botox®), Placebo | Ipsen | Glabellar Lines | 07/16 | 09/17 | | |
NCT01662492: A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine |
|
|
| Completed | 3 | 125 | US | Botulinum toxin type A Dose 1, onabotulinumtoxinA, BOTOX®, Botulinum toxin type A Dose 2, Placebo (Normal Saline) | Allergan | Migraine Disorders | 08/16 | 08/16 | | |
NCT03216408: Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 504 | NA | Neuronox, Clostridium Botulinum Toxin A 100 U, Botox, Clostridium Botulinum Toxin A 50 U | Medy-Tox | Glabellar Lines | 11/16 | 03/17 | | |
NCT03216473: Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Essential Blepharospasm |
|
|
| Completed | 3 | 140 | NA | Neuronox, Botulinum Toxin Type A for injection, Botox | Medy-Tox | Essential Blepharospasm | 03/17 | 07/17 | | |
| Withdrawn | 3 | 0 | US | onabotulinumtoxinA, BOTOX®, botulinum toxin type A | Allergan | Muscle Spasticity, Stroke | 05/17 | 05/17 | | |
| Completed | 3 | 384 | US, Europe, RoW | botulinum toxin Type A, BOTOX®, Normal Saline (Placebo) | Allergan | Pediatrics, Muscle Spasticity, Cerebral Palsy | 06/17 | 06/17 | | |
| Completed | 3 | 235 | Canada, US, Europe, RoW | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, Normal Saline (Placebo) | Allergan | Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke | 06/17 | 07/17 | | |
NCT01591746: Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction |
|
|
| Completed | 3 | 131 | US | Botulinum Toxin Type A, BOTOX, Placebo, Sodium chloride solution | Mayo Clinic, Allergan | Breast Cancer, Pain, Postoperative, BRCA1 Mutation, BRCA2 Mutation, Breast Diseases, Neoplasms | 07/17 | 07/17 | | |
FOLOTOX, NCT01821573: Study of the Effect of Botulinum Toxin Injection in Rectus Femoris and Triceps on the Length and the Strength During Locomotion in Chronic Hemiparetic Patients |
|
|
| Completed | 3 | 36 | Europe | botulinum toxin type A, Botox® allergan Inc, injection of NaCl 0.9% | Assistance Publique - Hôpitaux de Paris, Allergan | COMPARISON BETWEEN GROUP TREATED WITH BOTULINUM TOXIN AND PLACEBO | 09/17 | 05/19 | | |
| Completed | 3 | 250 | RoW | botulinum toxin type A, MEDITOXIN, BOTOX | Medy-Tox | Crow's Feet Lines | 12/17 | 05/18 | | |
NCT05380154: Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. |
|
|
| Completed | 3 | 500 | RoW | Botulinum Toxin A type for injection (Botulax®), Botulinum Toxin A type for injection (BOTOX®, Bao Tuo Shi®) | Hugel, Sihuan Pharmaceutical Limited | Glabellar Lines | 01/18 | 07/18 | | |
NCT02849418: Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 21 | Japan | GSK1358820, Placebo | GlaxoSmithKline | Urinary Bladder, Overactive | 03/18 | 12/18 | | |
2014-001068-36: Botox versus extended release tolterodine in the management ofoveractive bladder in children |
|
|
| Completed | 3 | 60 | Europe | Onabotulinum toxin A, Tolterodine, Tolterodine XL, Powder for injection, Capsule, hard, Botox, Tolterodine XL | Central Manchester University Hospitals NHS Foundation Trust, National Institute for Health Research | Idiopathic Overactive Bladder, Overactive bladder, Diseases [C] - Symptoms and general pathology [C23] | | | | |
NCT02820844: Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder |
|
|
| Completed | 3 | 250 | Japan | GSK1358820, Placebo, Antibiotic therapy, Bladder diary, King's Health Questionnaire (KHQ), Overactive Bladder Symptom Score (OABSS), Treatment Benefit Scale (TBS) | GlaxoSmithKline | Urinary Bladder, Overactive | 03/18 | 11/18 | | |
NCT03261167: A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity |
|
|
| Completed | 3 | 124 | Japan | Botulinum toxin A (GSK1358820), Placebo | GlaxoSmithKline | Spasticity, Post-Stroke | 03/18 | 01/19 | | |
NCT03289702: CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3) |
|
|
| Completed | 3 | 220 | RoW | CORETOX®, BOTOX® | Medy-Tox | Muscle Spasticity | 06/18 | 11/18 | | |
2016-003949-28: Efficacy and tolerability of incobotulinumtoxin A in comparison with onabotulinumtoxinA in patients with overactive bladder syndrome. Efficacia e tollerabilit¿ della incobotulinumtoxin A in confronto alla onabotulinumtoxin A nella terapia di pazienti con vescica iperattiva. |
|
|
| Terminated | 3 | 140 | Europe | xeomin, botox, Powder for solution for injection, XEOMIN - 100 UNITA' DL50 POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO DI VETRO, BOTOX - 100 UNIT¿ ALLERGAN POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO | PROF. ANTONELLA GIANNANTONI - CLINICA UROLOGICA - UNIVERSITà DI PERUGIA, Clinica Urologica ad indirizzo Oncologico | neurogenic overactive bladder Vescica iperattiva neurogena, neurogenic overactive bladder Vescica iperattiva neurogena, Diseases [C] - Symptoms and general pathology [C23] | | | | |
| Completed | 3 | 370 | Europe, US, RoW | Botulinum Toxin Type A, BOTOX®, OnabotulinumtoxinA | Allergan | Pediatrics, Muscle Spasticity, Cerebral Palsy | 08/18 | 08/18 | | |
| Completed | 3 | 220 | Europe, Canada, US, RoW | Botulinum Toxin Type A, BOTOX® OnabotulinumtoxinA | Allergan | Pediatrics, Muscle Spasticity, Cerebral Palsy, Stroke | 09/18 | 09/18 | | |
NCT01852045 / 2012-004877-26: Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity in Pediatric Patients |
|
|
| Completed | 3 | 114 | Europe, Canada, US, RoW | OnabotulinumtoxinA, BOTOX®, botulinum toxin Type A | Allergan | Urinary Incontinence | 10/18 | 10/18 | | |
NCT03440671: The Safety and Efficacy Study of Hutox Versus Botox® in Subject With Moderate to Severe Glabellar Lines |
|
|
| Unknown status | 3 | 260 | RoW | Hutox Inj, Botox Inj | Huons Co., Ltd. | Glabellar Frown Lines | 10/18 | 12/18 | | |
NCT01852058 / 2012-004898-30: A Long-Term Extension Study of OnabotulinumtoxinA (BOTOX®) for Urinary Incontinence Due to Neurogenic Detrusor Overactivity |
|
|
| Completed | 3 | 95 | Europe, Canada, US, RoW | OnabotulinumtoxinA, BOTOX®, botulinum toxin Type A | Allergan | Urinary Incontinence | 11/18 | 10/19 | | |
NCT03408236: Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines |
|
|
| Completed | 3 | 240 | RoW | Botulinum toxin type A, Botulax, Botox | Hugel | Crow's Feet Lines | 12/18 | 06/19 | | |
NCT03837561: The Efficacy and Safety of CUNOX® in Patients With Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 136 | RoW | Cunox, Botox | Medy-Tox | Glabellar Frown Lines | 03/19 | 06/19 | | |
NCT04081402: A Phase 1/3 Clinical Trial to Evaluate the Safety and Efficacy of HUTOX Compared to Botox® in Subjects With Moderate to Severe Crow's Feet Lines |
|
|
| Unknown status | 3 | 290 | RoW | HU-014, Botox Inj | Huons Co., Ltd. | Crow's Feet Lines | 11/19 | 02/20 | | |
NCT03223298: Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles |
|
|
| Completed | 3 | 75 | US | Botulinum toxin type A, Botulinum, Botox, Allergan, Botulinum Toxin A, 0.9% Sodium Chloride Injection, Saline, Placebo | Weill Medical College of Cornell University, New York Presbyterian Hospital, Allergan | Pain, Head, Pain Syndrome, Temporomandibular Disorder, Myofascial Pain Syndrome, Myofascial Pain | 03/20 | 03/20 | | |
NCT06354127: DWP450 for Treating Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 473 | RoW | DWP450, Botox® | Daewoong Pharmaceutical Co. LTD. | Moderate to Severe Glabellar Lines | 11/20 | 01/21 | | |
| Ongoing | 3 | 140 | Europe | Botox, Powder for solution for injection, Botox | Prof Mathias Abegg, Swiss National Science Foundation | Acquired esotropia (strabismus), Patients ( older than one year and younger than 17 years) with strabismus that requires an intervention., Body processes [G] - Ocular Physiological Phenomena [G14] | | | | |
NCT03193346: BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Participants With Chronic Migraine |
|
|
| Withdrawn | 3 | 0 | NA | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA, placebo (sodium chloride 0.9 mg) | Allergan | Migraine Disorders | 03/21 | 03/21 | | |
2021-000161-32: A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults with Upper Limb Spasticity Étude visant à comparer l’innocuité et l’efficacité du Dysport® par rapport au Botox® dans le traitement de patients adultes atteints de spasticité du membre supérieur |
|
|
| Not yet recruiting | 3 | 564 | Europe | Powder for solution for injection, Dysport® 500 U powder for solution for injection, Botox® 200 U powder for solution for injection | Ipsen Pharma, Ipsen Pharma | upper limb spasticity (ULS) of any aetiology (in US and France) or post-stroke ULS (in Canada) spasticité du membre supérieur (SMS) de toute étiologie (aux USA et en France) ou SMS postérieure à un accident vasculaire cérébral (au Canada), Upper limb spasticity is a medical condition when upper limb muscles are tight or in spasm and need to be relaxed. La spasticité du membre supérieur est une condition médicale dans laquelle les muscles dans membres supérieurs sont tendus ou contractés et ont besoin d'être relâchés, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04830345: Efficacy and Safety of Botulinum Toxin at Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 290 | RoW | ATGC-100 100U, Botox 100U | EuBiologics Co.,Ltd | Glabellar Frown Lines | 09/21 | 10/21 | | |
NCT03193359: Open Label Study of BOTOX® (Botulinum Toxin Type A) as Headache Prophylaxis in Chinese Patients With Chronic Migraine |
|
|
| Withdrawn | 3 | 0 | NA | botulinum toxin Type A, BOTOX®, onabotulinumtoxinA | Allergan | Migraine Disorders | 09/21 | 09/21 | | |
| Completed | 3 | 120 | Europe | BOTOX ® 200 Unités, Placebo | University Hospital, Clermont-Ferrand, Allergan | Essential Head Tremor | 09/21 | 09/22 | | |
NCT05059587: Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines |
|
|
| Completed | 3 | 318 | RoW | MBA-P01, BOTOX, OnabotulinumtoxinA | Medytox Korea | Glabellar Frown Lines | 12/21 | 03/22 | | |
NCT02097121 / 2014-000464-17: OnabotulinumtoxinA for the Treatment of Urinary Incontinence Due to Overactive Bladder in Pediatric Patients (12 to 17) |
|
|
| Terminated | 3 | 56 | Europe, Canada, US, RoW | BOTOX®, Botulinum Toxin Type A | Allergan | Urinary Incontinence, Urinary Bladder, Overactive | 02/22 | 02/22 | | |
NCT04073303: BOTOX® Treatment for Adults With a Wide Lower Face Due to Masseter Muscle Prominence |
|
|
| Completed | 3 | 377 | Canada, RoW | Botulinum Toxin Type A, OnabotulinumtoxinA, BOTOX®, Placebo | AbbVie | Masseter Muscle Prominence | 11/22 | 11/22 | | |
NCT04949399: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Moderate to Severe Platysma Prominence |
|
|
| Completed | 3 | 408 | Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | AbbVie | Platysma Prominence | 12/22 | 12/22 | | |
NCT05463965: A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 605 | RoW | QM1114-DP, OnabotulinumtoxinA, Placebo | Galderma R&D | Moderate to Severe Glabellar Lines | 01/23 | 06/23 | | |
NCT04994535 / 2021-000240-22: A Study To Assess the Safety and Effects of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 426 | Europe, Canada, US | OnabotulinumtoxinA, BOTOX, Placebo | AbbVie, AbbVie Inc. | Platysma Prominence | 06/23 | 06/23 | | |
2021-000240-22: A research study to evaluate safety and how well the study drug, BOTOX works for the treatment of platysma prominence (neck bands). |
|
|
| Not yet recruiting | 3 | 400 | Europe | BOTOX (botulinum toxin type A), Powder for solution for injection, BOTOX | AbbVie, AbbVie Inc. | Moderate and severe platysma prominence, Platysma prominence manifests as an undesirable aesthetic effect on the neck as vertical bands and along the jawline with blunting resulting from repetitive platysma muscle contraction., Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
NCT05364580: The Efficacy and Safety Study of Protoxin Versus Botox® in Subjects With Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 269 | RoW | PROTOXIN, Botox® | Protox Inc. | Glabellar Frown Lines | 06/23 | 10/23 | | |
NCT05134649: A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence |
|
|
| Completed | 3 | 292 | Canada, US | OnabotulinumtoxinA, BOTOX | AbbVie | Platysma Prominence | 08/23 | 08/23 | | |
NCT05804656: Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial |
|
|
| Completed | 3 | 300 | RoW | CKDB-501A, Botox® | CKD Bio Corporation | Glabellar Lines | 08/23 | 11/23 | | |
NCT06137287: A Study to Assess Adverse Events and Change of Masseter Muscle Prominence Using BOTOX Injections in Adult Participants |
|
|
| Completed | 3 | 259 | Japan | BOTOX, BOTOX VISTA, OnabotulinumtoxinA, Placebo for BOTOX | AbbVie | Masseter Muscle Prominence | 07/25 | 07/25 | | |
NCT06174688: A Study to Assess the Adverse Events and Effectiveness of BOTOX Injections for the Treatment of Moderate to Severe Forehead Lines in Chinese Adult Participants |
|
|
| Completed | 3 | 140 | RoW | BOTOX, Botulinum Toxin Type A, Placebo | AbbVie | Forehead Lines | 09/24 | 09/24 | | |
NCT06499688: A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 529 | RoW | Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA, Placebo | Chongqing Claruvis Pharmaceutical Co., Ltd. | Moderate to Severe Glabellar Lines | 03/24 | 05/24 | | |
NCT06387394: A Study to Assess BOTOX Injections in Adult Participants for the Change of Masseter Muscle Prominence |
|
|
| Completed | 3 | 202 | US | BOTOX, OnabotulinumtoxinA, Placebo | AbbVie | Masseter Muscle Prominence | 11/25 | 11/25 | | |
NCT06399718: A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants |
|
|
| Completed | 3 | 207 | US | BOTOX, OnabotulinumtoxinA, Placebo | AbbVie | Masseter Muscle Prominence | 11/25 | 11/25 | | |
NCT06585696: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) |
|
|
| Completed | 3 | 554 | RoW | CU-20101 treatment for Moderate to Severe Glabellar Striae | Cutia Therapeutics（Wuxi）Co.,Ltd | Glabellar Frown Lines | 11/25 | 11/25 | | |
